Trial Profile
A Phase I Study of Pevonedistat (MLN4924, TAK924) in Combination With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Pevonedistat (Primary)
- Indications B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 02 Jan 2024 Planned End Date changed from 2 Dec 2023 to 22 Jun 2024.
- 02 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 22 Jun 2024.
- 15 May 2023 Planned End Date changed from 2 Apr 2023 to 2 Dec 2023.